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with no evidence of dose-limiting
adverse events (AEs) (1).
Because anti-PCSK9 anti-
bodies may offer a therapeutic
option for patients on or off
statin therapy, the MENDEL-2
(Monoclonal Antibody Against
PCSK9 to Reduce Elevated
LDL-C in Subjects Currently
Not Receiving Drug Therapy for
Easing Lipid Levels-2) trial was
designed to evaluate the efﬁcacy
and safety of biweekly andmonthly evolocumab at doses anticipated for use in clinical
practice in a large population of patients with primary hy-
percholesterolemia not confounded by statin use or a history
of statin intolerance. The MENDEL-2 trial compared
subcutaneous (SC) evolocumab with placebo and blinded
oral ezetimibe, an agent widely used for patients unable to
tolerate statins.Methods
Patients. Following institutional review board approval and
informed consent, 71 study sites in 9 countries enrolled men
and women 18 to 80 years of age with fasting LDL-C
levels 100 mg/dl and <190 mg/dl, triglycerides 400
mg/dl, and 10-year Framingham coronary heart disease risk
scores 10% (2). Patients were randomized 1:1:1:1:2:2 to
oral placebo and SC placebo biweekly; oral placebo and
SC placebo monthly; ezetimibe and SC placebo biweekly;
ezetimibe and SC placebo monthly; oral placebo and=155
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n and Disposition (CONSORT Diagram)evolocumab 140 mg biweekly; or oral placebo and evolocu-
mab 420 mg monthly. Randomization was stratiﬁed by
LDL-C level (<130 mg/dl vs. 130 mg/dl). Patients and
study personnel were blinded to treatment assignment and
lipid results. Eligible patients could not have used lipid-
regulating drugs within 3 months of enrollment.
Key exclusion criteria, study drug preparation, laboratory
methods, and statistical analysis are described in the Online
Appendix.
Endpoints. Coprimary endpoints were percent change
from baseline in LDL-C level averaged at weeks 10 and 12
and at week 12. Key safety endpoints included the incidence
of treatment-emergent AEs, serious AEs, development of
anti-evolocumab antibodies, and increases of hepatic en-
zymes 3 times, bilirubin 2 times, and creatine kinase 5 times
above the upper limit of normal.Results
Patients. From January 21 through October 29, 2013, 615
patients were enrolled and randomly assigned to evolocumab
(n ¼ 306), placebo (n ¼ 155), or ezetimibe (n ¼ 154). One
patient randomized to placebo did not receive study drug
and was excluded from the analysis. Baseline characteristics
were balanced between groups (Table 1). Ninety-seven
percent of patients completed the study (Fig. 1).
Efﬁcacy outcomes. LDL-C. Signiﬁcant reductions in LDL-C
levels from baseline occurred within 2 weeks in both
biweekly and monthly evolocumab groups and were sub-
sequently sustained for the duration of the trial. At 12 weeks,
LDL-C levels had decreased from baseline, on average, by
57.0% (95% CI: 59.5% to 54.6%) with biweekly evolo-
cumab compared with 0.1% (95% CI: 3.2% to 3.4%) for615
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Table 1 Baseline Characteristics of Patients
Biweekly* Monthly
PBO q2w þ
PBO qd
n  76
PBO q2w þ
EZE qd
n  77
EVO 140 mg q2w þ
PBO qd
n  153
PBO Monthly þ
PBO qd
n  78
PBO Monthly þ
EZE qd
n  77
EVO 420 mg Monthly þ
PBO qd
n  153
Age, yrs 54  10 54  11 53  14 53  11 53  13 53  12
Male 28 (37) 24 (31) 49 (32) 13 (40) 25 (33) 52 (34)
Race
White 63 (83) 63 (82) 132 (86) 63 (81) 60 (78) 129 (84)
Black 4 (5) 6 (8) 9 (6) 6 (8) 6 (8) 9 (6)
Asian 9 (12) 7 (9) 12 (8) 8 (10) 10 (13) 12 (8)
Other 0 1 (1) 0 1 (1) 1 (1) 3 (2)
Lipid parameters
LDL-C, mg/dly 140  21 143  24 142  22 144  24 144  23 144  23
Apolipoprotein B, mg/dl 104  17 107  20 105  17 107  20 106  18 108  18
Lipoprotein(a), nmol/l 21 (9, 49) 28 (11, 120) 20 (7, 58) 22 (7, 62) 28 (12, 64) 28 (9, 104)
Non–HDL-C, mg/dl 167  26 169  29 167  26 173  31 169  27 170  27
Apolipoprotein A1, mg/dl 163  36 160  27 157  28 156  31 155  31 158  27
Apolipoprotein B/
apolipoprotein A1 ratio
0.7  0.2 0.7  0.2 0.7  0.2 0.7  0.2 0.7  0.2 0.7  0.2
Triglycerides, mg/dl 114 (83, 178) 113 (84, 158) 112 (82, 148) 118 (86, 179) 117 (90, 159) 119 (83, 169)
HDL-C, mg/dl 57 (44, 77) 59 (47, 70) 53 (45, 67) 54 (45, 66) 54 (42, 68) 57 (47, 66)
VLDL-C, mg/dl 23 (17, 34) 23 (17, 32) 23 (17, 30) 24 (17, 36) 24 (18, 32) 24 (17, 34)
TC/HDL-C ratio 4  1 4  1 4  1 4  1 4  1 4  1
Free PCSK9, ng/ml 281  89 270  94 272  81 270  82 265  94 274  84
Cardiovascular risk factors
Current cigarette use 6 (8) 11 (14) 13 (9) 8 (10) 15 (20) 19 (12)
Type 2 diabetes mellitus 0 0 0 1 (1) 0 0
Hypertension 12 (16) 19 (25) 53 (35) 19 (24) 23 (30) 50 (33)
Family history of premature CHD 4 (5) 10 (13) 20 (13) 2 (3) 7 (9) 18 (12)
Low HDL-C 20 (26) 14 (18) 36 (24) 21 (27) 26 (34) 31 (20)
2 CV risk factors 8 (11) 9 (12) 28 (18) 9 (12) 20 (26) 29 (19)
Risk factors for metabolic syndrome
Increased waist circumferencez 33 (43) 43 (56) 85 (56) 45 (58) 43 (56) 65 (43)
Triglycerides 150 mg/dl 26 (34) 21 (27) 37 (24) 25 (32) 23 (30) 48 (31)
Low HDL-Cx 20 (26) 14 (18) 36 (24) 21 (27) 26 (34) 31 (20)
Systolic blood pressure
130 mm Hg or diastolic
blood pressure85 mm Hg or
hypertension
34 (45) 44 (57) 93 (61) 41 (53) 43 (56) 88 (58)
Fasting glucose 110 mg/dl 12 (16) 19 (25) 30 (20) 22 (28) 14 (18) 31 (20)
Patients with baseline metabolic
syndrome (3 risk factors)
18 (24) 26 (34) 52 (34) 28 (36) 24 (31) 39 (26)
Blood pressure, mm Hg
Systolic 125  15 127  13 128  14 125  12 126  14 125  13
Diastolic 77  10 80  9 80  9 80  9 79  8 78  9
Glucose, mg/dl 92  9 94  10 93  8 95  11 92  10 94  10
Values are n (%), mean  SD, or median (Q1, Q3). *Every 2 weeks. yCalculated LDL-C was replaced by ultracentrifugation LDL-C from the same blood sample, if available, when calculated LDL-C was <40
mg/dl or triglycerides were >400 mg/dl. zDeﬁned as 102 cm for non-Asian men, 88 cm for non-Asian women, 90 cm for Asian men, and 80 cm for Asian women. xBaseline of <40 mg/dl in men
and <50 mg/dl in women.
CHD ¼ coronary heart disease; CV ¼ cardiovascular; EVO ¼ evolocumab; EZE ¼ ezetimibe; HDL-C ¼ high-density lipoprotein cholesterol; LDL-C ¼ low-density lipoprotein cholesterol; PBO ¼ placebo;
PCSK9 ¼ proprotein convertase subtilisin/kexin type 9; q2w ¼ every 2 weeks; qd ¼ daily; TC ¼ total cholesterol; VLDL-C ¼ very-low-density lipoprotein cholesterol.
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2533placebo and 17.8% (95% CI: 21.0% to 14.5%) for eze-
timibe (p < 0.001) (Fig. 2). For patients administered
monthly evolocumab, the mean 12-week LDL-C reduction
was 56.1% (95% CI: 58.3% to 53.9%) versus 1.3% (95%
CI:4.4% to 1.7%) for placebo and 18.6% (95%CI:21.6%
to 15.5%) for ezetimibe (p < 0.001). LDL-C percent
changes from baseline for the mean of weeks 10 and 12 andthe absolute mean reductions in LDL-C levels were signif-
icant in all evolocumab groups compared with placebo and
ezetimibe (p< 0.001) (Table 2). Patients in the evolocumab
groups achieved a level of LDL-C<70mg/dl atmuch higher
rates (72% and 69%) than placebo (0% and 1%) or ezetimibe
(2% and 1%) group patients for the mean of weeks 10 and
12 and at week 12, respectively. At week 12, LDL-C was
2keeW
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Figure 2 Percent Change in LDL-C Levels From Baseline to Week 12 With Evolocumab
(A) Biweekly. (B) Monthly. Vertical lines represent SE of the mean. Plot is based on observed data with no imputation for missing values. BL ¼ baseline; LDL-C ¼ low-density
lipoprotein cholesterol; SC ¼ subcutaneous.
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Figure 3
Individual Patient Percent Change in LDL-C Levels
From Baseline to Week 12 With Evolocumab
(A) Biweekly. (B) Monthly. *Patients who terminated SC or oral study drug early.
Abbreviations as in Figure 2.
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253459  22 mg/dl and 63  20 mg/dl with biweekly and
monthly evolocumab, respectively.
All patients treated with evolocumab experienced LDL-C
reductions compared with their individual baseline levels
versus 92.9% and 91.3% of ezetimibe-treated patients in the
biweekly and monthly groups (Fig. 3). Evolocumab treat-
ment in the biweekly and monthly groups led to LDL-C
decreases of >50% in 75.7% and 78.7% of patients when
evaluated by LDL-C level averaged at weeks 10 and 12 and
76.7% and 72.1% at week 12, respectively.
Evolocumab demonstrated consistent LDL-C effects
regardless of age, sex, race, region, or baseline levels of
LDL-C, triglycerides, or PCSK9 (Fig. 4), except for
biweekly evolocumab compared with placebo in patients
with metabolic syndrome, who had greater responses than
patients without metabolic syndrome (Fig. 4), an effect not
seen with monthly administration.
OTHER LIPIDS. Evolocumab signiﬁcantly decreased levels
of apolipoprotein B, lipoprotein a (Lp[a]), and non–
high-density lipoprotein cholesterol (HDL-C) and the ra-
tios of total cholesterol to HDL-C and apolipoprotein B
to apolipoprotein A1 (Table 2). Signiﬁcant HDL-C in-
creases were observed with evolocumab (p < 0.05). Tri-
glyceride and very-low-density lipoprotein cholesterol levels
were signiﬁcantly lowered with monthly evolocumab versus
0202
Evolocumab Monthly
vs Ezetimibe
Evolocumab Monthly
vs Placebo
Figure 4
Treatment Differences of Percent Change in LDL-C Levels From Baseline to Week 12 With Evolocumab Administered
Biweekly and Monthly Versus Placebo or Ezetimibe According to Subgroups of Patients
When the calculated LDL-C level was <40 mg/dl or triglycerides were >400 mg/dl, calculated LDL-C was replaced with ultracentrifugation LDL-C from the same blood sample, if
available. Least-squares mean differences and 95% CI are from the repeated-measures model. No imputation was used for missing values. BMI ¼ body mass index; CHD ¼
coronary heart disease; PCSK9 ¼ proprotein convertase subtilisin/kexin type 9; other abbreviations as in Figure 2.
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2535placebo or ezetimibe and in some comparisons in the
biweekly group.
Safety outcomes. Treatment-emergent AEs occurred in
134 evolocumab-treated patients (44%), 68 placebo-treated
patients (44%), and 70 ezetimibe-treated patients (46%)
(Table 3). No deaths or cardiovascular (CV) endpoints were
reported. Four serious AEs occurred in the evolocumab
groups (1.3%) versus 1 each in the placebo (0.6%) and
ezetimibe (0.6%) groups. In 2 cases, local investigators
considered that events were related to the study drug:
1) acute pancreatitis in a patient with a history of chole-
cystectomy, long-term alcohol intake, and concomitant
use of valproate semisodium on monthly evolocumab; and
2) transaminase and creatine kinase levels 8 times the upper
limit of normal in a patient on biweekly evolocumab that
returned to normal after study drug discontinuation. AEs
led to study drug discontinuation in 6 (3.9%), 5 (3.2%), and
7 (2.3%) patients in the placebo, ezetimibe, and evolocumab
groups, respectively.
Rates of potential muscle-related AEs and laboratory
abnormalities were comparable across treatment groups.
Injection-site reactions were reported in 5% of eachgroup; none led to discontinuation of study drug. No
neutralizing or binding antibodies were detected during the
study.
Discussion
In the largest monotherapy trial with a PCSK9 inhibitor
to date, evolocumab rapidly and markedly lowered
LDL-C and apolipoprotein B levels over 12 weeks
compared with placebo or ezetimibe. Evolocumab also
showed favorable effects on HDL-C, triglyceride, and Lp(a)
levels. The LDL-C reductions were comparable across
patient subgroups based on age, race, sex, or geographic
location, with all patients responding to therapy, as deﬁned
by LDL-C levels that decreased from baseline. LDL-C
reductions of >50% were reported in 72% of evolocumab
patients.
AEs, serious AEs, or events of interest occurred at
comparable rates between groups. Further, injection-site
reactions were infrequent and did not differ across groups
or between the evolocumab arms. Because of similar efﬁcacy
and tolerability between the evolocumab regimens studied,
Table 2 Lipid Efﬁcacy Outcomes Averaged at Weeks 10 and 12 and at Week 12
Biweekly Monthly
PBO q2w þ
PBO qd
(n ¼ 76)
PBO q2w þ
EZE qd
(n ¼ 77)
EVO 140 mg q2w þ
PBO qd
(n ¼ 153)
PBO Monthly þ
PBO qd
(n ¼ 78)
PBO Monthly þ
EZE qd
(n ¼ 77)
EVO 420 mg Monthly þ
PBO qd
(n ¼ 153)
LDL-C
% Change from baseline, mean of weeks 10 and 12* 0.4 (3.3, 2.4) 17.5 (20.4, 14.7) 56.9 (59.0, 54.8) 1.4 (4.1, 1.3) 19.1 (21.9, 16.4) 58.8 (60.8, 56.8)
Treatment difference vs. placebo 56.5 (60.0, 53.0) 57.4 (60.7, 54.1)
Treatment difference vs. ezetimibe 39.4 (42.9, 35.9) 39.7 (43.0, 36.4)
% Change from baseline, week 12* 0.1 (3.2, 3.4) 17.8 (21.0, 14.5) 57.0 (59.5, 54.6) 1.3 (4.4, 1.7) 18.6 (21.6, 15.5) 56.1 (58.3, 53.9)
Treatment difference vs. placebo 57.1 (61.1, 53.1) 54.8 (58.5, 51.1)
Treatment difference vs. ezetimibe 39.3 (43.3, 35.3) 37.6 (41.2, 33.9)
Adjustedy p value vs. placebo <0.001 <0.001
Adjustedy p value vs. ezetimibe <0.001 <0.001
Other lipid parameters
Apolipoprotein B
% Change from baseline, mean of weeks 10 and 12 0.05 (2.9, 3.0) 13.5 (16.5, 10.5) 47.0 (49.3, 44.8) 1.5 (1.2, 4.3) 14.8 (17.6, 11.9) 49.4 (51.4, 47.4)
Treatment difference vs. placebo 47.1 (50.7, 43.5) 50.9 (54.3, 47.6)
Treatment difference vs. ezetimibe 33.6 (37.2, 30.0) 34.6 (38.0, 31.3)
% Change from baseline, week 12 0.6 (2.5, 3.7) 13.2 (16.3, 10.1) 47.2 (49.5, 44.9) 1.8 (1.2, 4.9) 14.0 (17.1, 11.0) 46.6 (48.8, 44.4)
Treatment difference vs. placebo 47.8 (51.6, 44.1) 48.4 (52.1, 44.8)
Treatment difference vs. ezetimibe 34.0 (37.8, 30.3) 32.6 (36.2, 28.9)
Adjustedy p value vs. placebo <0.001 <0.001
Adjustedy p value vs. ezetimibe <0.001 <0.001
Lipoprotein (a)z
% Change from baseline, mean of weeks 10 and 12 0.1 (11.1, 11.5) 0.0 (9.6, 10.3) 18.4 (37.5, 0.0) 0.0 (11.8, 8.3) 2.1 (18.2, 5.6) 19.2 (38.8, 4.8)
Treatment difference vs. placebo 18.5 (25.3, 11.7) 19.2 (23.2, 15.3)
Treatment difference vs. ezetimibe 18.4 (24.4, 12.4) 17.2 (23.2, 11.1)
% Change from baseline, week 12 0.0 (8.5, 17.5) 0.0 (9.1, 12.5) 20.4 (39.5, 0.0) 0.0 (10.5, 8.1) 2.1 (17.2, 8.3) 17.8 (38.5, 0.0)
Treatment difference vs. placebo 20.4 (27.8, 13.1) 17.8 (24.5, 11.1)
Treatment difference vs. ezetimibe 20.4 (28.1, 12.7) 15.8 (24.4, 7.1)
Adjustedy p value vs. placebo <0.001 <0.001
Adjustedy p value vs. ezetimibe <0.001 <0.001
Non–HDL-C
% Change from baseline, mean of weeks 10 and 12 1.4 (4.1, 1.2) 14.6 (17.3, 12.0) 50.2 (52.2, 48.3) 1.3 (1.1, 3.8) 16.5 (19.0, 14.0) 52.0 (53.7, 50.2)
Treatment difference vs. placebo 48.8 (52.0, 45.6) 53.3 (56.2, 50.3)
Treatment difference vs. ezetimibe 35.6 (38.8, 32.4) 35.5 (38.4, 32.5)
% Change from baseline, week 12 0.3 (3.2, 2.6) 14.9 (17.8, 12.0) 50.1 (52.3, 48.0) 1.5 (1.2, 4.2) 16.5 (19.2, 13.7) 49.7 (51.7, 47.7)
Treatment difference vs. placebo 49.8 (53.3, 46.3) 51.2 (54.5, 47.9)
Treatment difference vs. ezetimibe 35.2 (38.7, 31.7) 33.2 (36.5, 29.9)
Adjustedy p value vs. placebo <0.001 <0.001
Adjustedy p value vs. ezetimibe <0.001 <0.001
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Table 2 Continued
Biweekly Monthly
PBO q2w þ
PBO qd
(n ¼ 76)
PBO q2w þ
EZE qd
(n ¼ 77)
EVO 140 mg q2w þ
PBO qd
(n ¼ 153)
PBO Monthly þ
PBO qd
(n ¼ 78)
PBO Monthly þ
EZE qd
(n ¼ 77)
EVO 420 mg Monthly þ
PBO qd
(n ¼ 153)
Apolipoprotein B/apolipoprotein A1 ratio
% Change from baseline, mean of weeks 10 and 12 1.0 (2.3, 4.3) 13.4 (16.7, 10.1) 48.1 (50.6, 45.7) 3.9 (0.4, 7.3) 14.5 (18.0, 11.0) 51.1 (53.6, 48.6)
Treatment difference vs. placebo 49.1 (53.1, 45.1) 55.0 (59.1, 50.8)
Treatment difference vs. ezetimibe 34.7 (38.7, 30.7) 36.6 (40.8, 32.4)
% Change from baseline, week 12 1.1 (2.4, 4.6) 12.7 (16.2, 9.2) 48.5 (51.0, 45.9) 4.5 (0.8, 8.3) 14.3 (18.1, 10.5) 48.3 (51.0, 45.5)
Treatment difference vs. placebo 49.6 (53.8, 45.4) 52.8* (57.3, 48.3)
Treatment difference vs. ezetimibe 35.8 (40.0, 31.6) 34.0 (38.5, 29.5)
Adjustedy p value vs. placebo <0.001 <0.001
Adjustedy p value vs. ezetimibe <0.001 <0.001
Triglyceridesz
% Change from baseline, mean of weeks 10 and 12 3.9 (18.9, 11.2) 1.5 (15.0, 18.4) 9.2 (24.2, 11.0) 4.9 (12.7, 31.7) 4.0 (17.7, 10.4) 15.7 (28.2, 6.4)
Treatment difference vs. placebo 5.3 (13.3, 2.7) 20.6 (31.0, 10.2)
Treatment difference vs. ezetimibe 7.7 (16.9, 1.5) 11.7 (21.2, 2.3)
% Change from baseline, week 12 1.9 (18.6, 11.5) 0.0 (13.3, 17.5) 8.1 (26.1, 10.1) 2.0 (16.6, 33.8) 2.4 (19.34, 12.9) 15.6 (30.0, 1.5)
Treatment difference vs. placebo 6.2 (16.4, 4.0) 17.7 (21.7, 8.6)
Treatment difference vs. ezetimibe 8.1 (17.5, 1.3) 13.2 (21.7, 4.8)
Adjustedy p value vs placebo 0.72 <0.001
Adjustedy p value vs ezetimibe 0.027 0.044
HDL-Cz
% Change from baseline, mean of weeks 10 and 12 1.6 (8.4, 5.0) 0.9 (10.1, 7.3) 3.9 (1.4, 11.6) 4.7 (10.6, 0.6) 0.0 (7.0, 8.7) 3.8 (2.6, 11.9)
Treatment difference vs. placebo 5.5 (2.2, 8.8) 8.5 (5.5, 11.4)
Treatment difference vs. ezetimibe 4.8 (0.9, 8.8) 3.8 (0.8, 8.4)
% Change from baseline, week 12 1.2 (9.1, 6.1) 2.8 (8.6, 8.7) 4.8 (2.9, 12.8) 5.3 (11.3, 2.3) 1.5 (6.7, 8.2) 4.1 (2.7, 11.2)
Treatment difference vs. placebo 5.9 (1.7, 10.2) 9.3 (5.3, 13.3)
Treatment difference vs. ezetimibe 7.6 (3.1, 12.0) 5.5 (2.2, 8.8)
Adjustedy p value vs. placebo 0.007 <0.001
Adjustedy p value vs. ezetimibe 0.013 0.044
VLDL-Cz
% Change from baseline, mean of weeks 10 and 12 3.8 (19.2, 10.0) 2.7 (16.5, 16.7) 8.4 (25.4, 10.9) 4.2 (13.6, 27.9) 3.3 (20.0, 9.5) 16.2 (28.0, 5.5)
Treatment difference vs. placebo 4.6 (11.3, 2.1) 20.4 (30.1, 10.7)
Treatment difference vs. ezetimibe 5.7 (14.1, 2.7) 12.8 (22.1, 3.5)
% Change from baseline, week 12 1.6 (20.0, 10.5) 0.9 (12.3, 12.9) 9.5 (26.8, 10.3) 0.0 (16.7, 33.3) 3.6 (19.2, 14.3) 16.3 (30.7, 2.5)
Treatment difference vs. placebo 7.9 (18.8, 2.9) 16.3 (25.6, 7.0)
Treatment difference vs. ezetimibe 8.6 (18.1, 0.9) 12.7 (20.9, 4.5)
Adjustedy p value vs. placebo 0.72 <0.001
Adjustedy p value vs. ezetimibe 0.082 0.044
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2538future clinical decisions about administration may reﬂect
individual patient preferences for biweekly or monthly
treatment.
The task of deﬁning appropriate target populations
for anti-PCSK9 therapy will likely generate vigorous
debate. Evidence suggests that substantial beneﬁts should
accrue from additional incremental LDL-C reductions in
at-risk patients, including results from randomized clinical
trials, meta-analyses, and Mendelian randomization studies
(3–6). However, the demonstration of incremental im-
provements in clinical outcomes derived from “highly”
compared with “moderately” effective statin regimens
contrasts with the lack of beneﬁt observed in randomized
trials adding fenoﬁbrate or niacin to patients already
receiving stable statin doses (7,8). Based largely on these
ﬁndings, recent American College of Cardiology (ACC)/
American Heart Association (AHA) treatment guidelines
advocated using high doses of effective statin therapy and
de-emphasized LDL-C targets when treating hypercho-
lesterolemia (9).
Although the ACC/AHA task force tried to simplify lipid
management by emphasizing statin use, the guidelines
acknowledged the limits of statin therapy. Subsequently, the
researchers recommended nonstatin therapies reported to
improve outcomes in clinical trials when patients have
inadequate response to statins or remain at high risk despite
statin therapy (Section 6.3.2) (9). This guidance will likely
require reevaluation given the large LDL-C reductions
produced by evolocumab and other investigational medicines
(10) compared with older nonstatin therapies. Cost con-
siderations will also require evaluation.
The MENDEL-2 trial used ezetimibe as a comparator
because we anticipate that as with ezetimibe, PCSK9 in-
hibitors will ﬁnd use predominantly as second-line therapy
to statins. Clinicians often prescribe ezetimibe, an agent
currently under investigation for its effect on CV outcomes,
as monotherapy for hypercholesterolemia in patients who
cannot tolerate statins or as combination therapy for those
requiring additional lipid effects while receiving statins
(11). Given the greater lipid effects of anti-PCSK9 anti-
bodies compared with ezetimibe, several hyperlipidemic
populations might derive incremental beneﬁts from this
novel treatment approach. The largest of these groups
consists of statin-intolerant patients. Other groups include
patients with historically poor LDL-C–lowering re-
sponses to statins, those with statin contraindications due
to drug-drug interactions, and those with elevations of
Lp(a) levels, an independent CV risk factor that is not
responsive to statins. Additionally, parenteral therapy may
produce better lipid results in a subset of patients who
experience particular difﬁculty with daily oral treatment
compliance.
Study limitations. Although the MENDEL-2 trial dem-
onstrated favorable efﬁcacy and tolerability within a large
cohort not receiving statins, the study did not speciﬁcally
evaluate statin intolerance or elevated Lp(a) levels. By
Table 3 Adverse Events
Placebo Ezetimibe Evolocumab
PBO q2w þ
PBO qd
(n ¼ 76)
PBO Monthly þ
PBO qd
(n ¼ 78)
PBO q2w þ
EZE qd
(n ¼ 77)
PBO Monthly þ
EZE qd
(n ¼ 77)
EVO 140 mg q2w þ
PBO qd
(n ¼ 153)
EVO 420 mg Monthly þ
PBO qd
(n ¼ 153)
Treatment emergent AEs
Any 34 (45) 34 (44) 35 (46) 35 (46) 73 (48) 61 (40)
Serious* 0 1 (1) 0 1 (1) 3 (2) 1 (1)
Leading to discontinuation
of study drug
3 (4) 3 (4) 4 (5) 1 (1) 4 (3) 3 (2)
Treatment-related seriousy 0 0 0 0 1 (1) 1 (1)
Deaths 0 0 0 0 0 0
Common treatment-emergent AEsz
Headache 3 (4) 1 (1) 4 (5) 1 (1) 5 (3) 5 (3)
Diarrhea 5 (7) 1 (1) 2 (3) 1 (1) 4 (3) 5 (3)
Nasopharyngitis 1 (1) 2 (3) 4 (5) 2 (3) 3 (2) 3 (2)
Muscle and liver function labs
Creatine kinase >5  ULN 1 (1) 1 (1) 0 0 1 (1) 1 (1)
Creatine kinase >10  ULN 1 (1) 1 (1) 0 0 1 (1) 0
ALT or AST >3  ULNx 2 (3) 3 (4) 1 (1) 0 3 (2) 0
ALT or AST >5  ULN 1 (1) 1 (1) 0 0 1 (1) 0
Total bilirubin at week 12, mmol/l 7.3  3.4 8.3  4.4 8.0  4.1 8.2  4.8 7.8  3.9 7.5  4.1
Potential muscle eventsk 3 (4) 3 (4) 2 (3) 3 (4) 6 (4) 2 (1)
Myalgia 1 (1) 2 (3) 2 (3) 1 (1) 2 (1) 1 (1)
Musculoskeletal pain 2 (3) 0 0 1 (1) 3 (2) 0
Potential injection-site reactionsk 2 (3) 6 (8) 4 (5) 3 (4) 10 (7) 6 (4)
Erythema 0 3 (4) 1 (1) 1 (1) 4 (3) 1 (1)
Pain 0 2 (3) 0 1 (1) 2 (1) 3 (2)
Bruising 0 2 (3) 2 (3) 1 (1) 3 (2) 0
Antibodies
Binding NA NA NA NA 0 0
Neutralizing NA NA NA NA 0 0
Neurocognitive AEs{ 0 0 0 0 0 0
Values are n (%) or mean  SD. *Deﬁned as fatal, life threatening, requiring or prolonging hospital admission, causing persistent or substantial disability, incapacity, or a congenital anomaly or birth defect.
yTreatment-related AEs were those considered possibly related to the study drug by the investigator. zReported in 5% of patients in one or more treatment arms. xElevated levels led to study drug
discontinuation in 1 placebo and 1 evolocumab patient. kSearched using standard Medical Dictionary for Regulatory Activities queries with a broad search strategy; reported in3% of patients in one or more
treatment arms. {Searched using HLGT terms: deliria (including confusion); cognitive and attention disorders and disturbances; dementia and amnestic conditions; disturbances in thinking and perception;
mental impairment disorders.
AE ¼ adverse event; ALT ¼ alanine aminotransferase; AST ¼ aspartate aminotransferase; NA ¼ not applicable; ULN ¼ upper limit of normal; other abbreviations as in Table 1.
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2539design, as an early evaluation of the safety and efﬁcacy of
evolocumab monotherapy at doses anticipated for use in
clinical practice, the MENDEL-2 study enrolled patients
with Framingham risk scores 10%, some of whom might
not receive drug therapy under the new guidelines. Future
studies should reﬁne the target populations for anti-PCSK9
monotherapy by enrolling higher-risk patients with statin
intolerance, severe statin nonresponsiveness, or isolated
Lp(a) elevations.
An additional limitation of the MENDEL-2 trial was the
12-week duration. Hyperlipidemia requires chronic admin-
istration of therapy; therefore, ongoing studies of evolocu-
mab will require extended observation periods. To date,
these assessments have appeared favorable (12). Continued
open-label monitoring and future outcomes trials will ulti-
mately provide a better understanding of the AE proﬁle,
particularly the long-term acceptance of parenteral therapy
for hypercholesterolemia and the development of antidrug
antibodies. Further, longer-term observation of treatedpatients who fail statins, either due to inadequate efﬁcacy or
intolerance, will address how anti-PCSK9 monotherapy
may ﬁt into the treatment paradigm for hyperlipidemia.
Conclusions
The MENDEL-2 trial demonstrated robust reductions in
LDL-C levels with evolocumab monotherapy in adults with
hypercholesterolemia regardless of sex, age, race, or CV risk
factors. LDL-C reductions were comparable between
biweekly and monthly administration, with good tolerability
and safety. Based on these favorable results, the MENDEL-2
study provides the rationale for future investigations
involving higher-risk patients who might beneﬁt from
anti-PCSK9 monotherapy.
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For an expanded Methods section, please see the online version of this
article.
